What’s New in the Biologics CMO Space in APAC?
- As more biologics products enter and exit clinical development and into the market in the APAC region, the opportunities for CMOs to fulfil production requirements are burgeoning.
- There is an increase in demand for innovative process technologies to meet the demand.
- Biopharmaceutical companies in APAC are moving away from in-house manufacturing and recruiting CMOs to meet production requirements while they invest in R&D, marketing and analytics.
With the Chinese Contract Manufacturing Market growing at over 15% year-on-year as more biologics products move through clinical development to commercialization, there is major opportunity for domestic and global payers alike. Because of the early stage the market is in, there is a push for facilities equipped with innovative process technologies and adoption of single use technology and continuous bioprocessing. Among the key players investing in the manufacturing space are Boehringer Ingelheim, WuXi Biologics and Transcenta. Global stakeholders in the CMO space are teaming up with key domestic players such as the partnership between Boehringer Ingelheim and BeiGene, Lonza and Junshi Biosciences and more, in efforts to support Chinese biopharmaceutical clients.
Likewise, there is an upward trajectory of CMO market growth in APAC. Since 2019, biologics drug products held the largest market share in the biopharmaceutical contract manufacturing market in the Asia Pacific region and as more biologics products enter and exit clinical development and into the market, the opportunities for CMOs to fulfil production requirements are burgeoning. Similarly, there is a rise in innovative process technologies to meet the demand. However, not all countries are quick in adopting such technologies.
Due to the ongoing advancements in cell culture, 68% of them are now using mammalian expression system with Chinese CMOs having the greatest number of mammalian cell culture systems, a shift from the microbial fermentation of the past, today. On the other hand, South Korea has the greatest number of bioprocessing facilities equipped with microbial cell culture systems. Eubiologics and Hanmi Pharmaceuticals’ facilities are examples of such facilities. Similarly, South Korea bioprocessing facilities are moving towards a hybrid mode of production, whereby they either build a stainless-steel plant or retrofit single-use systems (SUS), depending on the expression systems used. For instance, microbial facilities are mostly equipped with stainless-steel bioreactors. Meanwhile, adoption of single use bioreactors has been observed in more than 51% facilities in the APAC, especially in regions like China, Taiwan and Hong Kong.
While there is inertia in some countries like South Korea in adopting newer process technologies, there is significant push for such innovative technologies in other countries and thereby, APAC on the whole. Many CMOs are, therefore, rising to the occasion to meet the demand. With bigger product pipelines in APAC’s biopharmaceutical companies, CMOs are shifting towards SUS systems to enable faster commercialization. When compared to traditional stainless-steel equipment, single- use technologies have been shown to reduce capital and operating costs by 40-50% and 20-30%, respectively, and time-to-build by 30%. This is complimented with a shift in biopharmaceutical companies away from in-house manufacturing and recruiting CMOs to meet production requirements while they invest in R&D, marketing and analytics.
This article is brought to you by IMAPAC’s market research team. For more on the details of the APAC Bioprocessing sector, check our Market Reports or Dashboards.